Immunotherapy startup CytomX raises $70M; IPO on horizon
The Bay Area immunotherapy player targets PD-L1 and "Probody" drug conjugates. It'll use the $70 million to advance several candidates into the clinic.
What will Novartis’ multiple sclerosis pill cost? (Morning Read)
Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. Gilenya will go head-to-head with injectable medicines, including Avonex, Tysabri and Rebif. But how much will the MS pill cost? Novartis won't say, NPR reports.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.